Shares of Medivation Inc. (NASDAQ:MDVN) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $62.98 and last traded at $62.52, with a volume of 707,895 shares changing hands. The stock had previously closed at $62.33.

A number of analysts have recently issued reports on MDVN shares. Canaccord Genuity reiterated a “hold” rating and issued a $45.00 price objective on shares of Medivation in a report on Tuesday, March 29th. Wedbush reiterated a “buy” rating on shares of Medivation in a report on Saturday, April 30th. Leerink Swann reiterated a “hold” rating and issued a $39.00 price objective on shares of Medivation in a report on Thursday, March 31st. SunTrust Banks Inc. reiterated a “buy” rating and issued a $56.00 price objective on shares of Medivation in a report on Tuesday, April 19th. Finally, Barclays PLC reiterated a “buy” rating on shares of Medivation in a report on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $71.76.

The company has a 50-day moving average of $60.15 and a 200 day moving average of $47.34. The firm has a market capitalization of $10.22 billion and a PE ratio of 41.71.

Medivation (NASDAQ:MDVN) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.12. During the same period in the previous year, the company posted $0.17 earnings per share. The firm earned $182.50 million during the quarter, compared to analysts’ expectations of $197.01 million. Medivation’s revenue was up 41.3% on a year-over-year basis. On average, analysts forecast that Medivation Inc. will post $1.30 EPS for the current year.

In other news, SVP Andrew Kenneth William Powell sold 2,578 shares of the firm’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $60.42, for a total transaction of $155,762.76. Following the completion of the sale, the senior vice president now directly owns 28,517 shares of the company’s stock, valued at approximately $1,722,997.14. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Rick Bierly sold 10,340 shares of the firm’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $59.76, for a total value of $617,918.40. Following the sale, the chief financial officer now directly owns 35,059 shares of the company’s stock, valued at $2,095,125.84. The disclosure for this sale can be found here.

Several large investors have made changes to their positions in MDVN. Advisors Asset Management Inc. raised its stake in shares of Medivation by 16.6% in the fourth quarter. Advisors Asset Management Inc. now owns 25,952 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 3,688 shares in the last quarter. TD Asset Management Inc. raised its stake in shares of Medivation by 9.5% in the fourth quarter. TD Asset Management Inc. now owns 28,804 shares of the biopharmaceutical company’s stock valued at $1,392,000 after buying an additional 2,500 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. raised its stake in shares of Medivation by 7.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. now owns 29,559 shares of the biopharmaceutical company’s stock valued at $1,429,000 after buying an additional 1,979 shares in the last quarter. Andra AP fonden raised its stake in shares of Medivation by 19.5% in the fourth quarter. Andra AP fonden now owns 30,600 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 5,000 shares in the last quarter. Finally, Schroder Investment Management Group acquired a new stake in shares of Medivation during the fourth quarter valued at about $1,710,000.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.